Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetic patients (WHO criterion, 1999)~* 19kg/m2 ≤ BMI ≤ 35kg/m2~* Subject with the initial treatment of SUs on the basis of controlling diet and sport; treatment lasting for no less than 3 months and stable dose for at least 1 month; HbA1c 7-11%~* No insulin therapy during 6 months before being selected~* Not involved in any drug test during 3 months before being selected~* No serious heart, liver or kidney diseases~* Must have effective contraception methods for women of child-bearing age~* Willing to being informed consent~Exclusion Criteria:~* Type 1 diabetes or other specific types of diabetes~* Pregnancy, preparation for pregnancy, lactation and women of child-bearing age incapable of effective contraception methods~* Uncooperative subject because of various reasons~* Abnormal liver function, glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic transaminase (AST) \> twice the upper limits of normal~* Impairment of renal function, serum creatinine: ≥ 133mmol/L for female，≥ 135mmol/L for male~* Serious chronic gastrointestinal diseases~* Edema~* Serious heart diseases, such as cardiac insufficiency (level III or more according to NYHA), acute coronary syndrome and old myocardial infraction~* Blood pressure: Systolic blood pressure (SBP) ≥ 180mmHg and/or diastolic blood pressure (DBP) ≥ 110mmHg~* White blood count (WBC) \< 4.0×109/L or platelet count (PLT) \< 90×109/L，or definite anemia (Hb：\< 120g/L for male, \< 110g/L for female), or other hematological diseases~* Endocrine system diseases, such as hyperthyroidism and hypercortisolism~* Experimental drug allergy or frequent hypoglycemia~* Psychiatric disorders, drug or other substance abuse~* Diabetic ketoacidosis and hyperosmolar nonketotic coma requiring insulin therapy~* Stressful situations such as surgery, serious trauma and so on~* Chronic hypoxic diseases such as pulmonary emphysema and pulmonary heart disease~* Combined use of drugs effecting glucose metabolism such as glucocorticoid~* Tumor, especially bladder tumor and/or family history of bladder tumor and/or long-term hematuria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone and Metformin (Type: EXPERIMENTAL): Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).